Search

Your search keyword '"Olson, Peter"' showing total 1,149 results

Search Constraints

Start Over You searched for: Author "Olson, Peter" Remove constraint Author: "Olson, Peter"
1,149 results on '"Olson, Peter"'

Search Results

2. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

3. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

4. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

5. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

6. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

8. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

14. Boundary regions

21. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

23. Doing More with Less: How One Professional Development School Partnership Strategically Aligned Ideals and Resources

24. Turbulent heat exchange between water and ice at an evolving ice-water interface

25. Experiments on the fragmentation of a buoyant liquid volume in another liquid

26. Quantifying melt production and degassing rate at mid‐ocean ridges from global mantle convection models with plate motion history

27. Performance benchmarks for a next generation numerical dynamo model

28. Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer

29. Figure S1 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

30. Table S2 from TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

33. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

34. Supplementary Table S2 from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

35. Supplementary Figure S6 from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

37. Supplementary Materials and Methods from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

38. Data from MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

40. Turbulent metal-silicate mixing, fragmentation, and equilibration in magma oceans

43. Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X‑Ray Cocrystallography.

45. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

Catalog

Books, media, physical & digital resources